When the Supreme Court decided Dobbs v. Jackson, Americans were told a simple story: abortion policy would return to the states. Whatever one’s moral view, the constitutional logic was clear. States would once again be allowed to regulate abortion according to their own laws, voters, and medical standards.
That promise now looks increasingly hollow.
In practice, federal agencies still control the most consequential part of abortion policy: access. And through inaction, delay, and litigation strategy, the federal government is quietly nullifying state abortion laws without repealing a single statute.
Follow LifeNews.com on Instagram for pro-life pictures and videos.
The clearest example is the abortion drug mifepristone.
After Dobbs, multiple states enacted laws restricting or banning abortion. Yet abortion pills continue to arrive in those states by mail, often prescribed remotely, frequently without meaningful medical oversight. States can pass laws, but they cannot control a federally regulated drug pipeline that the Food and Drug Administration refuses to police.
That is not federalism. It is preemption by neglect.
The FDA approved mifepristone in 2000 under conditions that assumed in-person medical supervision. Since then, the regulatory landscape has changed dramatically. During COVID, the Biden administration loosened requirements, allowing pills to be mailed without an in-person visit. Those changes were never meaningfully reversed, even after the pandemic ended and new safety data accumulated.
Today, women can obtain abortion pills through online portals, sometimes from out-of-state or foreign entities, without an exam, without screening for ectopic pregnancy, and without verified informed consent. The drug’s own FDA label includes a black-box warning acknowledging serious risks, including emergency room visits. Yet enforcement is virtually nonexistent.
When states attempt to respond, the federal government intervenes not by enforcing safety standards, but by blocking accountability.
Several states have sued the FDA, arguing that the agency’s refusal to revisit or enforce its own rules undermines their authority to regulate medicine within their borders. Rather than addressing the merits, the Department of Justice has asked courts to pause these cases, arguing lack of standing and urging deference while the FDA conducts a “review” that has dragged on without resolution.
The result is paralysis.
States cannot enforce their laws. Courts are asked to wait. The FDA does nothing. Pills keep shipping.
This is not neutrality. It is a policy choice.
Supporters of Dobbs were told that returning abortion to the states would respect democratic self-governance. But sovereignty without enforcement is an illusion. A state’s authority means little if federal agencies control distribution channels and refuse to act when state laws are openly circumvented.
The contradiction is especially striking given the political rhetoric surrounding Dobbs. Federalism was celebrated. States’ rights were praised. Yet when states now assert those rights, federal agencies respond by shielding access rather than enforcing rules.
Even more troubling is the precedent this sets beyond abortion.
If the FDA can effectively override state medical regulations by declining to enforce its own safety protocols, what stops similar behavior in other areas of medicine? If litigation can be stalled indefinitely by claiming future review, what does regulatory accountability mean at all?
Federal power does not require aggressive action to dominate. Sometimes all it takes is refusal to act.
This debate is often framed as pro-life versus pro-choice. That framing misses what is happening structurally. The issue here is not simply abortion. It is whether states retain meaningful authority after Dobbs, or whether federal agencies can quietly reassert control without legislation, without public debate, and without responsibility.
There is still a federal role in abortion policy. Even Dobbs did not deny that. But that role was never meant to function as a backdoor override of state law.
If federal agencies believe abortion pills should be universally accessible regardless of state restrictions, they should say so openly and seek that authority through Congress. What they should not do is achieve the same result through delay, ambiguity, and selective enforcement.
Dobbs promised clarity. What we have instead is a regulatory fog that leaves states powerless, women uninformed, and federal agencies unaccountable.
If returning abortion to the states was meant to mean anything, it cannot end at the mailbox.
